Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory conditions
Biotech
Novartis lines up another potential indication for BTK inhibitor
Novartis’ BTK inhibitor remibrutinib reduced disease activity in patients with the skin disease hidradenitis suppurativa during a midstage trial.
Annalee Armstrong
Mar 9, 2024 12:00pm
MoonLake's IL-17 drug wins 'meet or beat' trial vs. competition
Jun 26, 2023 11:18am
Aclaris stock sinks after phase 2a skin trial flop
Mar 6, 2023 11:29am
Manufacturing concerns sideline INmune's US Alzheimer's trial
May 24, 2022 9:44am
Chasing Novartis and Roche, Ventus banks $140M for clinical work
Feb 9, 2022 8:12am
IMIDomics emerges with $16.5M for new approach to inflammation
Jul 27, 2021 7:00am
